Amelioration of bendrofluazide-induced hypokalemia by timolol.
The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant. Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio. There was no evidence of a shift of potassium from the intracellular to the extracellular space.
D001539:Bendroflumethiazide / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced / Q000188:drug therapy*; D007424:Intracellular Fluid / Q000187:drug effects / Q000378:metabolism; D008297:Male; D011188:Potassium / Q000378:metabolism; D011412:Propanolamines / Q000627:therapeutic use*; D012964:Sodium / Q000378:metabolism; D013999:Timolol / Q000494:pharmacology / Q000627:therapeutic use*
D011412:Propanolamines; D001539:Bendroflumethiazide; D013999:Timolol; D012964:Sodium; D011188:Potassium